Our present study on Avn-C demonstrated both anti-amyloid and anti-tau properties by lowering the amyloidogenic processing proteins BACE1 and APP, which reduces the Aβ1-42 production and prevents tau hyperphosphorylation at Ser 202, 396, 404, and Thr 231 sites in the hippocampal tissue, effectively preventing amyloid- and tau-mediated disease advancement in AD mouse models. The gene discussed is APP; the disease is Alzheimer disease.